Response rates by patient and disease characteristics in the older AML population (N = 176)
| Variable . | CR rates (%) . | P . |
|---|---|---|
| Overall | N = 176 | - |
| Treatment group | ||
| High intensity | 10/31 (32) | .46 |
| Intermediate intensity | 3/11 (27) | |
| INV/low intensity | 30/134 (22) | |
| Cytogenetics group | ||
| Adverse | 12/70 (17) | .08 |
| Nonadverse | 31/106 (29) | |
| Age, y | ||
| 60-70 | 24/84 (29) | .21 |
| >70 | 19/92 (21) | |
| AHD type | ||
| MDS | 39/163 (23) | .92 |
| Non-MDS | 4/16 (37.5) | |
| t-AML | ||
| Yes | 9/36 (25) | .9 |
| No | 34/140 (26) | |
| WBCs* | ||
| <10 | 29/119 (24) | .17 |
| ≥10 | 6/38 (16) | |
| Platelets* | ||
| ≥50 | 21/103 (20) | .43 |
| <50 | 14/54 (26) | |
| BM blasts | ||
| <30% | 20/72 (27) | .48 |
| ≥30% | 23/104 (22) | |
| AHD therapy | ||
| HMA/lenalidomide/thalidomide | 31/158 (20) | .34 |
| Other | 6/21 (29) | |
| Variable . | CR rates (%) . | P . |
|---|---|---|
| Overall | N = 176 | - |
| Treatment group | ||
| High intensity | 10/31 (32) | .46 |
| Intermediate intensity | 3/11 (27) | |
| INV/low intensity | 30/134 (22) | |
| Cytogenetics group | ||
| Adverse | 12/70 (17) | .08 |
| Nonadverse | 31/106 (29) | |
| Age, y | ||
| 60-70 | 24/84 (29) | .21 |
| >70 | 19/92 (21) | |
| AHD type | ||
| MDS | 39/163 (23) | .92 |
| Non-MDS | 4/16 (37.5) | |
| t-AML | ||
| Yes | 9/36 (25) | .9 |
| No | 34/140 (26) | |
| WBCs* | ||
| <10 | 29/119 (24) | .17 |
| ≥10 | 6/38 (16) | |
| Platelets* | ||
| ≥50 | 21/103 (20) | .43 |
| <50 | 14/54 (26) | |
| BM blasts | ||
| <30% | 20/72 (27) | .48 |
| ≥30% | 23/104 (22) | |
| AHD therapy | ||
| HMA/lenalidomide/thalidomide | 31/158 (20) | .34 |
| Other | 6/21 (29) | |
Data available on baseline WBCs and platelets in 157 of 176 evaluable patients.